Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 12/20 | 0.63 |
| ▸ | TPO | P07202 | 10/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.63 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.44 |
| ▸ | PNP | P00491 | 1/20 | 0.44 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2460010 | 0.88 | MPO (0.65) | MPOTPOCYP3A4KCNH2RXFP1 | |
| SCHEMBL2454888 | 0.82 | MPO (0.47) | MPOTPOCYP3A4KCNH2ALDH1A1 | |
| SCHEMBL2286263 | 0.75 | MPO (0.59) | MPOTPOCYP3A4KCNH2PNP | |
| SCHEMBL2456512 | 0.74 | MPO (0.54) | MPOTPOCYP3A4KCNH2PNP | |
| SCHEMBL27223343 | 0.73 | MPO (0.61) | MPOTPOCYP3A4KCNH2PNP | |
| SCHEMBL27231694 | 0.73 | MPO (0.61) | MPOTPOCYP3A4KCNH2PNP | |
| SCHEMBL27223961 | 0.73 | MPO (0.61) | MPOTPOCYP3A4KCNH2PNP | |
| SCHEMBL27223956 | 0.73 | MPO (0.57) | MPOTPOCYP3A4KCNH2PNP | |
| SCHEMBL1460860 | 0.73 | MPO (1.00) | MPOTPOCYP3A4KCNH2ALDH1A1 | |
| SCHEMBL2286250 | 0.73 | MPO (0.77) | MPOTPOCYP3A4KCNH2PNP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020021300-A1 | USE OF MYELOPEROXIDASE (MPO) INHIBITORS FOR THE TREATMENT OF CHEMORESISTANT ACUTE MYELOID LEUKEMIA (AML) | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2020-01-30 | — | — | WO | claimed |
| US-20140221400-A1 | USE OF MYELOPEROXIDASE (MPO) INHIBITORS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF TO TREAT MULTIPLE SYSYEM ATROPHY (MSA) 938 | ASTRAZENECA AB (SE) | 2014-08-07 | — | — | US | claimed |
| US-20130059870-A1 | USE OF MYELOPEROXIDASE (MPO) INHIBITORS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF TO TREAT MULTIPLE SYSYEM ATROPHY (MSA) 938 | ASTRAZENECA AB (SE) | 2013-03-07 | — | — | US | claimed |
| EP-2010535-B1 | THIOXANTHINE DERIVATIVES AND THEIR USE AS INHIBITORS OF MPO | ASTRAZENECA AB (SE) | 2012-07-11 | — | — | EP | claimed |
| US-8026244-B2 | Thioxanthine derivatives and their use as inhibitors of MPO | ASTRAZENECA AB (SE) | 2011-09-27 | — | — | US | claimed |
| US-20110207755-A1 | USE OF MYELOPEROXIDASE (MPO) INHIBITORS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF TO TREAT MULTIPLE SYSYEM ATROPHY (MSA) 938 | ASTRAZENECA AB (SE) | 2011-08-25 | — | — | US | claimed |
| EP-2200616-A1 | MIPO INHIBITORS FOR THE TREATMENT OF HUNTINGTON'S DISEASE AND MULTIPLE SYSTEM ATROPHY | AstraZeneca AB (SE) | 2010-06-30 | — | — | EP | claimed |
| US-20090149475-A1 | Thioxanthine Derivatives and Their Use as Inhibitors of MPO | ASTRAZENECA AB (SE) | 2009-06-11 | — | — | US | claimed |
| WO-2009025618-A1 | MIPO INHIBITORS FOR THE TREATMENT OF HUNTINGTON'S DISEASE AND MULTIPLE SYSTEM ATROPHY | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | WO | claimed |
| US-20090054468-A1 | New Use 938 | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | US | claimed |
| CN-113633641-A | MPO inhibitors for the treatment of huntington's disease and multiple system atrophy | 阿斯利康(瑞典)有限公司 | 2021-11-12 | — | — | CN | disclosed |
| WO-2021013942-A1 | USE OF MYELOPEROXIDASE INHIBITORS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES IN PATIENTS SUFFERING FROM MYELOPROLIFERATIVE NEOPLASMS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2021-01-28 | — | — | WO | disclosed |
| US-20200405724-A1 | USE OF MYELOPEROXIDASE (MPO) INHIBITORS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF TO TREAT MULTIPLE SYSTEM ATROPHY (MSA) 938 | ASTRAZENECA AB (SE) | 2020-12-31 | — | — | US | disclosed |
| US-10772890-B2 | Use of myeloperoxidase (MPO) inhibitors or pharmaceutically acceptable salts thereof to treat multiple system atrophy (MSA) 938 | ASTRAZENECA AB (SE) | 2020-09-15 | — | — | US | disclosed |
| WO-2020021300-A1 | USE OF MYELOPEROXIDASE (MPO) INHIBITORS FOR THE TREATMENT OF CHEMORESISTANT ACUTE MYELOID LEUKEMIA (AML) | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2020-01-30 | — | — | WO | disclosed |
| US-20090149475-A1 | Thioxanthine Derivatives and Their Use as Inhibitors of MPO | ASTRAZENECA AB (SE) | 2009-06-11 | — | — | US | disclosed |
| WO-2009025617-A1 | COMBINATIONS CONTAINING MPO INHIBITORS AGAINST NEUROINFLAMMATORY DISORDERS | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | WO | disclosed |
| US-20090053176-A1 | New Combination 937 | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | US | disclosed |
| WO-2009025618-A1 | MIPO INHIBITORS FOR THE TREATMENT OF HUNTINGTON'S DISEASE AND MULTIPLE SYSTEM ATROPHY | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | WO | disclosed |
| US-20090054468-A1 | New Use 938 | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10772890-B2 | Use of myeloperoxidase (MPO) inhibitors or pharmaceutically acceptable salts thereof to treat multiple system atrophy (MSA) 938 | MPO, CAT, SOD1 | MPO 1/4885TPO 35/4885CYP3A4 3017/4885 |
| US-20140221400-A1 | USE OF MYELOPEROXIDASE (MPO) INHIBITORS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF TO TREAT MULTIPLE SYSYEM ATROPHY (MSA) 938 | MPO, CAT, HTT | MPO 1/4885TPO 87/4885CYP3A4 2838/4885 |
| US-20200405724-A1 | USE OF MYELOPEROXIDASE (MPO) INHIBITORS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF TO TREAT MULTIPLE SYSTEM ATROPHY (MSA) 938 | MPO, CAT, HTT | MPO 1/4885TPO 28/4885CYP3A4 3083/4885 |
| US-20130059870-A1 | USE OF MYELOPEROXIDASE (MPO) INHIBITORS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF TO TREAT MULTIPLE SYSYEM ATROPHY (MSA) 938 | MPO, CAT, HTT | MPO 1/4885TPO 87/4885CYP3A4 2838/4885 |
| US-20090053176-A1 | New Combination 937 | MPO, PARK7, CAT | MPO 1/4885TPO 253/4885CYP3A4 3867/4885 |
| US-20090149475-A1 | Thioxanthine Derivatives and Their Use as Inhibitors of MPO | MPO, XDH, EPX | MPO 1/4885TPO 12/4885CYP3A4 1227/4885 |
| US-20090054468-A1 | New Use 938 | MPO, CAT, HTT | MPO 1/4885TPO 199/4885CYP3A4 3883/4885 |
| US-20110207755-A1 | USE OF MYELOPEROXIDASE (MPO) INHIBITORS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF TO TREAT MULTIPLE SYSYEM ATROPHY (MSA) 938 | MPO, CAT, HTT | MPO 1/4885TPO 87/4885CYP3A4 2838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.